Raw Data Library
About
Aims and ScopeAdvisory Board Members
More
Who We Are?
User Guide
Green Science
​
​
EN
Sign inGet started
​
​

About
Aims and ScopeAdvisory Board Members
More
Who We Are?
User GuideGreen Science

Language

Sign inGet started
RDL logo

Verified research datasets. Instant access. Built for collaboration.

Navigation

About

Aims and Scope

Advisory Board Members

More

Who We Are?

Add Raw Data

User Guide

Legal

Privacy Policy

Terms of Service

Support

Got an issue? Email us directly.

Email: info@rawdatalibrary.netOpen Mail App
​
​

© 2025 Raw Data Library. All rights reserved.
PrivacyTerms
  1. Raw Data Library
  2. /
  3. Publications
  4. /
  5. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days

Verified authors • Institutional access • DOI aware
50,000+ researchers120,000+ datasets90% satisfaction
Preprint
en
2020

The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days

0 Datasets

0 Files

en
2020
Vol 9
Vol. 9
DOI: 10.12688/f1000research.26707.1

Get instant academic access to this publication’s datasets.

Create free accountHow it works

Frequently asked questions

Is access really free for academics and students?

Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.

How is my data protected?

Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.

Can I request additional materials?

Yes, message the author after sign-up to request supplementary files or replication code.

Advance your research today

Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.

Get free academic accessLearn more
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaboration
Access Research Data

Join our academic network to download verified datasets and collaborate with researchers worldwide.

Get Free Access
Institutional SSO
Secure
This PDF is not available in different languages.
No localized PDFs are currently available.
John P A Ioannidis
John P A Ioannidis

Stanford University

Verified
Perrine Janiaud
Cathrine Axfors
Janneke van ’t Hooft
+31 more

Abstract

Background: Never before have clinical trials drawn as much public attention as those testing interventions for COVID-19. We aimed to describe the worldwide COVID-19 clinical research response and its evolution over the first 100 days of the pandemic.Methods:Descriptive analysis of planned, ongoing or completed trials by April 9, 2020 testing any intervention to treat or prevent COVID-19, systematically identified in trial registries, preprint servers, and literature databases. A survey was conducted of all trials to assess their recruitment status up to July 6, 2020.Results:Most of the 689 trials (overall target sample size 396,366) were small (median sample size 120; interquartile range [IQR] 60-300) but randomized (75.8%; n=522) and were often conducted in China (51.1%; n=352) or the USA (11%; n=76). 525 trials (76.2%) planned to include 155,571 hospitalized patients, and 25 (3.6%) planned to include 96,821 health-care workers. Treatments were evaluated in 607 trials (88.1%), frequently antivirals (n=144) or antimalarials (n=112); 78 trials (11.3%) focused on prevention, including 14 vaccine trials. No trial investigated social distancing. Interventions tested in 11 trials with >5,000 participants were also tested in 169 smaller trials (median sample size 273; IQR 90-700). Hydroxychloroquine alone was investigated in 110 trials. While 414 trials (60.0%) expected completion in 2020, only 35 trials (4.1%; 3,071 participants) were completed by July 6. Of 112 trials with detailed recruitment information, 55 had recruited <20% of the targeted sample; 27 between 20-50%; and 30 over 50% (median 14.8% [IQR 2.0-62.0%]).Conclusions:The size and speed of the COVID-19 clinical trials agenda is unprecedented. However, most trials were small investigating a small fraction of treatment options. The feasibility of this research agenda is questionable, and many trials may end in futility, wasting research resources. Much better coordination is needed to respond to global health threats.

How to cite this publication

Perrine Janiaud, Cathrine Axfors, Janneke van ’t Hooft, Ramon Saccilotto, Arnav Agarwal, Christian Appenzeller‐Herzog, Despina G. Contopoulos‐Ioannidis, Valentin Danchev, Ulrich Dirnagl, Hannah Ewald, Gerald Gartlehner, Steven N. Goodman, Noah Haber, Angeliki Ioannidis, John P A Ioannidis, Mark P. Lythgoe, Wenyan Ma, Malcolm Macleod, Mario Malički, Joerg J Meerpohl, Min Yan, David Moher, Blin Nagavci, Florian Naudet, Christiane Pauli‐Magnus, Jack W. O’Sullivan, Nico Riedel, Benno Röthlisberger, Mandy Sauermann, Stefan Schandelmaier, Andreas M. Schmitt, Benjamin Speich, Paula Williamson, Lars G. Hemkens (2020). The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. , 9, DOI: https://doi.org/10.12688/f1000research.26707.1.

Related publications

Why join Raw Data Library?

Quality

Datasets shared by verified academics with rich metadata and previews.

Control

Authors choose access levels; downloads are logged for transparency.

Free for Academia

Students and faculty get instant access after verification.

Publication Details

Type

Preprint

Year

2020

Authors

34

Datasets

0

Total Files

0

Language

en

DOI

https://doi.org/10.12688/f1000research.26707.1

Join Research Community

Access datasets from 50,000+ researchers worldwide with institutional verification.

Get Free Access